EMD Serono chooses Miguel Fernández Alcalde to lead healthcare in North America
- Miguel Fernández Alcalde is appointed as President of EMD Serono on December 10, 2024.
- He has previously served as Chief Operating Officer and has a substantial background in healthcare leadership.
- The appointment aims to enhance EMD Serono's growth in the U.S. biopharmaceutical market.
In a significant leadership transition, EMD Serono, the healthcare arm of Merck KGaA, Darmstadt, Germany, has announced the appointment of Miguel Fernández Alcalde as its new President as of December 10, 2024. This decision comes as the company aims to strengthen its market position in the U.S., an essential part of its global healthcare strategy. Prior to this appointment, Fernández Alcalde had a robust history within the company, having served as the Chief Operating Officer for EMD Serono for the past 18 months as well as holding various leadership roles, including Chief of Staff for the CEO of Healthcare and General Manager positions in multiple European countries. His extensive experience within the healthcare sector and his commitment to addressing unmet medical needs position him well for this new role. He takes over from Chris Round, who is retiring after a successful eight-year tenure during which he led successful market launches and nurtured talent development within the organization. Round played a crucial role in establishing the foundations for the company’s growth and success in the competitive U.S. biopharmaceutical landscape.